0001551152-22-000012.txt : 20220429 0001551152-22-000012.hdr.sgml : 20220429 20220429090002 ACCESSION NUMBER: 0001551152-22-000012 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220429 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220429 DATE AS OF CHANGE: 20220429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 22870582 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K 1 abbv-20220429.htm 8-K abbv-20220429
0001551152false00015511522022-04-292022-04-290001551152exch:XNYSus-gaap:CommonStockMember2022-04-292022-04-290001551152exch:XCHIus-gaap:CommonStockMember2022-04-292022-04-290001551152abbv:Sec1500SeniorNotesDue2023Memberexch:XNYS2022-04-292022-04-290001551152exch:XNYSabbv:Sec1.375SeniorNotesDue2024Member2022-04-292022-04-290001551152exch:XNYSabbv:Sec1250SeniorNotesDue2024Member2022-04-292022-04-290001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2022-04-292022-04-290001551152exch:XNYSabbv:Sec2.125SeniorNotesdue2028Member2022-04-292022-04-290001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2022-04-292022-04-290001551152exch:XNYSabbv:Sec2125SeniorNotesDue2029Member2022-04-292022-04-290001551152abbv:Sec1.250SeniorNotesdue2031Memberexch:XNYS2022-04-292022-04-29

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 _____________________________________________________
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): April 29, 2022
 
ABBVIE INC.
(Exact name of registrant as specified in its charter)
Delaware 001-35565 32-0375147
(State or other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation)   Identification No.)
 _____________________________________________________
1 North Waukegan Road
North ChicagoIllinois 60064-6400
(Address of principal executive offices)(Zip Code)
 
Registrant’s telephone number, including area code:  (847) 932-7900
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.01 Par Value ABBV New York Stock Exchange
Chicago Stock Exchange
1.500% Senior Notes due 2023ABBV23BNew York Stock Exchange
1.375% Senior Notes due 2024ABBV24New York Stock Exchange
1.250% Senior Notes due 2024ABBV24BNew York Stock Exchange
0.750% Senior Notes due 2027ABBV27New York Stock Exchange
2.125% Senior Notes due 2028ABBV28New York Stock Exchange
2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange
2.125% Senior Notes due 2029ABBV29New York Stock Exchange
1.250% Senior Notes due 2031ABBV31New York Stock Exchange
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company    
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    



Item 2.02  Results of Operations and Financial Condition
 
On April 29, 2022, AbbVie Inc. issued a press release announcing financial results for the first quarter ended March 31, 2022.  A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits
Exhibit No. Exhibit
 
104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).




SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  ABBVIE INC.
   
Date:April 29, 2022By:/s/ Robert A. Michael
  Robert A. Michael
  Vice Chairman, Finance and Commercial Operations and
  Chief Financial Officer

 


EX-99.1 2 abbv-20220331xexhibit991.htm EX-99.1 Document


abbvieimage1a53.jpg
PRESS RELEASE
 
AbbVie Reports First-Quarter 2022 Financial Results
 
Reports First-Quarter Diluted EPS of $2.51 on a GAAP Basis, an Increase of 26.1 Percent; Adjusted Diluted EPS of $3.16, an Increase of 9.3 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share related to Acquired IPR&D and Milestones Expense 1

Delivers First-Quarter Net Revenues of $13.538 Billion, an Increase of 4.1 Percent on a Reported Basis and 5.4 Percent Operationally

First-Quarter Global Net Revenues from the Immunology Portfolio Were $6.141 Billion, an Increase of 6.9 Percent on a Reported Basis, or 8.1 Percent on an Operational Basis; U.S. Humira Net Revenues Were $3.993 Billion, an Increase of 2.2 Percent; Internationally, Humira Net Revenues Were $743 Million, a Decrease of 22.6 Percent on a Reported Basis, or 17.9 Percent on an Operational Basis, Due to Biosimilar Competition; Global Skyrizi Net Revenues Were $940 Million; Global Rinvoq Net Revenues Were $465 Million

First-Quarter Global Net Revenues from the Hematologic Oncology Portfolio Were $1.646 Billion, a Decrease of 1.6 Percent on a Reported Basis, or 0.6 Percent on an Operational Basis; Global Imbruvica Net Revenues Were $1.173 Billion, a Decrease of 7.4 Percent, with U.S. Net Revenues of $874 Million and International Profit Sharing of $299 Million; Global Venclexta Net Revenues Were $473 Million

First-Quarter Global Net Revenues from the Neuroscience Portfolio Were $1.488 Billion, an Increase of 19.2 Percent on a Reported Basis, or 20.4 Percent on an Operational Basis; Global Botox Therapeutic Net Revenues Were $614 Million; Vraylar Net Revenues Were $427 Million

First-Quarter Global Net Revenues from the Aesthetics Portfolio Were $1.374 Billion, an Increase of 20.5 Percent on a Reported Basis, or 22.5 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $641 Million; Global Juvederm Net Revenues Were $410 Million

Updates 2022 Adjusted Diluted EPS Guidance Range from $14.00 - $14.20 to $13.92 - $14.12, which Includes an Unfavorable Impact of $0.08 Per Share Related to Acquired IPR&D and Milestones Expense Incurred During the First Quarter 2022
 
NORTH CHICAGO, Ill., April 29, 2022 – AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2022.
 
"This year is off to a strong start. Our first quarter results highlight the diversity of our portfolio and include compelling performance from key growth drivers Skyrizi, Rinvoq, Aesthetics and Neuroscience,” said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. “Our momentum combined with ramping contributions from new products and new indications will drive accelerating revenue and EPS growth through the rest of the year."

Note: "Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.

1 Beginning in the first quarter 2022, AbbVie includes the impact of upfront and milestone payments related to collaborations, licensing agreements and other asset acquisitions in its reported non-GAAP financial measures.
1


First-Quarter Results

Worldwide net revenues were $13.538 billion, an increase of 4.1 percent on a GAAP basis, or 5.4 percent on an operational basis.

Global net revenues from the immunology portfolio were $6.141 billion, an increase of 6.9 percent on a reported basis, or 8.1 percent on an operational basis.
Global Humira net revenues of $4.736 billion decreased 2.7 percent on a reported basis, or 1.8 percent on an operational basis. U.S. Humira net revenues were $3.993 billion, an increase of 2.2 percent. Internationally, Humira net revenues were $743 million, a decrease of 22.6 percent on a reported basis, or 17.9 percent on an operational basis, due to biosimilar competition.
Global Skyrizi net revenues were $940 million, an increase of 63.7 percent on a reported basis, or 65.6 percent on an operational basis.
Global Rinvoq net revenues were $465 million, an increase of 53.6 percent on a reported basis, or 57.3 percent on an operational basis.

Global net revenues from the hematologic oncology portfolio were $1.646 billion, a decrease of 1.6 percent on a reported basis, or 0.6 percent on an operational basis.
Global Imbruvica net revenues were $1.173 billion, a decrease of 7.4 percent, with U.S. net revenues of $874 million and international profit sharing of $299 million.
Global Venclexta net revenues were $473 million, an increase of 16.9 percent on a reported basis, or 21.1 percent on an operational basis.

Global net revenues from the neuroscience portfolio were $1.488 billion, an increase of 19.2 percent on a reported basis, or 20.4 percent on an operational basis.
Global Botox Therapeutic net revenues were $614 million, an increase of 15.4 percent on a reported basis, or 16.6 percent on an operational basis.
Vraylar net revenues were $427 million, an increase of 23.4 percent.
Global Ubrelvy net revenues were $138 million.

Global net revenues from the aesthetics portfolio were $1.374 billion, an increase of 20.5 percent on a reported basis, or 22.5 percent on an operational basis.
Global Botox Cosmetic net revenues were $641 million, an increase of 34.4 percent on a reported basis, or 36.6 percent on an operational basis.
Global Juvederm net revenues were $410 million, an increase of 27.5 percent on a reported basis, or 30.9 percent on an operational basis.

On a GAAP basis, the gross margin ratio in the first quarter was 70.1 percent. The adjusted gross margin ratio was 84.5 percent.

On a GAAP basis, selling, general and administrative expense was 23.1 percent of net revenues. The adjusted SG&A expense was 21.1 percent of net revenues.

On a GAAP basis, research and development expense was 11.1 percent of net revenues. The adjusted R&D expense was 10.9 percent of net revenues.

Acquired IPR&D and milestones expense was 1.1 percent of net revenues.

On a GAAP basis, the operating margin in the first quarter was 34.8 percent. The adjusted operating margin was 51.4 percent, which includes an unfavorable 110 basis point impact from acquired IPR&D and milestones expense.

Net interest expense was $539 million.

On a GAAP basis, the tax rate in the quarter was 8.8 percent. The adjusted tax rate was 12.1 percent.

Diluted EPS in the first quarter was $2.51 on a GAAP basis. Adjusted diluted EPS, excluding specified items, was $3.16. These results include an unfavorable impact of $0.08 per share related to acquired IPR&D and milestones expense.
Note: "Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.
2


Recent Events

AbbVie announced that the U.S. Food and Drug Administration (FDA) approved Rinvoq (upadacitinib, 45 mg (induction dose) and 15 mg and 30 mg (maintenance dose)) for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. The approval is supported by data from two Phase 3 induction studies and one maintenance study. In these studies, significantly more patients treated with Rinvoq achieved the primary and all secondary endpoints compared to placebo. The safety of Rinvoq, including the 45 mg dose as induction therapy, in these studies was generally consistent with the known safety profile of Rinvoq, with no new important safety risks observed. This approval marks the first indication for Rinvoq in gastroenterology and represents Rinvoq’s fourth FDA approved indication.

AbbVie announced positive top-line results from the Phase 3 induction study U-EXCEL, which showed Rinvoq (45 mg, once daily) achieved both primary endpoints of clinical remission and endoscopic response, compared to placebo at week 12, as well as most key secondary endpoints in patients with moderate to severe Crohn’s disease (CD). The safety results in this study were consistent with the known profile of Rinvoq, with no new safety risks observed. U-EXCEL is the second of two Phase 3 induction studies to evaluate the safety and efficacy of Rinvoq in adults with moderate to severe CD and full results will be presented at upcoming medical conferences and published in a peer-reviewed journal. Positive top-line results from the Phase 3 portion of the first induction study, U-EXCEED, were announced in December 2021 and the maintenance study for both clinical trials is ongoing.

AbbVie announced that the FDA extended the review period for Skyrizi (risankizumab) for the treatment of moderate to severe CD by three months to review additional data submitted by AbbVie, including information about the on-body injector. Currently approved indications for Skyrizi were not affected by this extension. Skyrizi is a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.

AbbVie announced that it resolved all U.S. Humira (adalimumab) litigation with Alvotech. Under the terms of the resolution, AbbVie will grant Alvotech a non-exclusive license to its Humira-related patents in the U.S., which will begin on July 1, 2023. AbbVie will make no payments of any form to Alvotech, and Alvotech will pay royalties to AbbVie for licensing its Humira patents and acknowledges the validity and enforceability of the licensed patents. The resolution included dismissal of the patent and trade secret litigation between AbbVie and Alvotech.

At the Congress of European Crohn’s and Colitis Organization (ECCO), AbbVie shared 26 abstracts, including 16 oral and digital oral presentations, that reinforced AbbVie’s commitment to research that helps advance standards of care for inflammatory bowel disease (IBD) patients. Highlights included new post-hoc analyses from the pivotal Phase 3 Skyrizi program in CD as well as results from a post-hoc analysis of Phase 3 Rinvoq pivotal trials evaluating UC symptoms.

At the American Academy of Dermatology (AAD) Annual Meeting, AbbVie and Allergan Aesthetics presented new research that demonstrated their shared commitment to advancing science across a spectrum of dermatologic conditions and aesthetic indications. The research included new data on the efficacy, durability and safety of Rinvoq and Skyrizi as well as data from across the Allergan Aesthetics portfolio.

AbbVie and Genmab announced topline results from the first cohort of the EPCORE NHL-1 phase 1/2 clinical trial evaluating epcoritamab (DuoBody-CD3xCD20) in patients with relapsed/refractory large B-cell lymphoma (LBCL) who received at least two prior lines of systemic therapy. Results from this cohort demonstrated a confirmed overall response rate (ORR) of 63.1 percent with a 12-month median duration of response. Based on the topline results, the companies will engage global regulatory authorities and data from the clinical trial will be presented at a future medical meeting. Epcoritamab is being co-developed by AbbVie and Genmab.






3


Recent Events (Continued)

At the American Association of Cancer Research (AACR) Annual Meeting, AbbVie presented positive results from a Phase 2 trial evaluating navitoclax in combination with ruxolitinib in patients with myelofibrosis that previously had a suboptimal response or disease progression with ruxolitinib monotherapy. The study evaluated 34 patients and median overall survival was not reached for patients who had a ≥ 1 grade improvement in bone marrow fibrosis (BMF) or ≥ 20% variant allele frequency (VAF) reduction. Additionally, at the time of analysis with > 2 year follow up, the survival estimate was 100% in patients who had improvements in BMF or VAF.

AbbVie announced that it submitted a supplemental New Drug Application (sNDA) to the FDA for Vraylar (cariprazine) for the adjunctive treatment of major depressive disorder (MDD). The submission is based on clinical trial results that showed clinically and statistically significant improvement in the Montgomery-Asberg Depression Rating Scale (MADRS) total score in patients with MDD treated with Vraylar and an antidepressant. If approved, this milestone will be the fourth indication for Vraylar joining approvals for the treatment of adults with schizophrenia, the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of depressive episodes associated with bipolar I disorder. Vraylar is being co-developed by AbbVie and Gedeon Richter Plc.

AbbVie announced that the Phase 3 PROGRESS trial evaluating Qulipta (atogepant), an oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the preventive treatment of chronic migraine in adults, met its primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to placebo, for both the 60 mg once daily (QD) and 30 mg twice daily (BID) doses, across the 12-week treatment period. The study also demonstrated statistically significant improvement in all secondary endpoints and the overall safety profile of Qulipta was consistent with safety findings observed in previous studies with an episodic migraine population. Data from this study will support a submission to expand the use of Qulipta to include preventive treatment of chronic migraine in the U.S. and additional submissions globally.

At the American Academy of Neurology (AAN) Annual Meeting, AbbVie shared 30 abstracts demonstrating the breadth of its neuroscience portfolio. The abstracts highlighted AbbVie’s continued migraine treatment research across the spectrum of the disease, AbbVie’s commitment to patients with advanced Parkinson’s disease and new studies in spasticity and cervical dystonia.

AbbVie and Gedeon Richter Plc. (Richter) announced a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases. The collaboration is based on the results of preclinical research carried out by Richter and includes several new chemical entities selected for development. AbbVie and Richter have collaborated for 15 years on Central Nervous System (CNS) projects, including globally launched products such as Vraylar.

AbbVie announced the successful completion of its acquisition of Syndesi Therapeutics SA. The acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118, which is currently being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders, such as Alzheimer's disease and MDD.

Allergan Aesthetics announced that the FDA approved Juvederm Volbella XC for improvement of infraorbital (undereye) hollows in adults over the age of 21. With this approval, Juvederm Volbella XC became the first and only dermal filler to receive FDA approval for the improvement of infraorbital hollows.

At the Aesthetic and Anti-aging Medicine World Congress (AMWC), Allergan Aesthetics presented research that demonstrated its commitment to the future of aesthetics with a forward-facing trends report. The meeting also marked Allergan Aesthetics’ entry into the emerging category of Hybrid Injectables with the launch of HArmonyCa with lidocaine across Europe. The dual-effect Hybrid Injectable contains two active ingredients, hyaluronic acid, a well-known ingredient found in facial fillers, and calcium hydroxyapatite (CaHA), which is known to help stimulate collagen production.



4


Recent Events (Continued)

AbbVie announced positive results from the Phase 3 VIRGO trial evaluating the safety and efficacy of investigational twice-daily administration of Vuity (pilocarpine HCl ophthalmic solution) 1.25% in adults with age-related blurry near vision (presbyopia). Additional details of this trial will be presented at future medical congresses and will serve as the basis for a sNDA submission for an optional twice-daily administration to the FDA in the second quarter of 2022. Approved by the FDA in October 2021 for once-daily use, Vuity is the first and only eye drop to treat age-related blurry near vision in adults.

At the American Glaucoma Society (AGS) Annual Meeting and the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, AbbVie presented data from its leading portfolio of eye care treatments. Highlights included updated analyses that help further scientific understanding of Durysta (bimatoprost intracameral implant), a first-of-its-kind biodegradable implant to lower eye pressure for glaucoma patients; new data on the Xen Gel Stent, a surgical implant designed to lower high eye pressure approved for refractory glaucoma patients; and new data on Vuity 1.25%.

AbbVie and Scripps Research, an independent, non-profit biomedical research and drug discovery institute, announced a global collaboration to develop potential novel, direct-acting antiviral treatments for COVID-19.




5


Full-Year 2022 Outlook
AbbVie is updating its adjusted diluted EPS guidance range for the full-year 2022 from $14.00 - $14.20 to $13.92 - $14.12 which includes an unfavorable impact of $0.08 per share related to acquired IPR&D and milestones expense incurred during the first quarter 2022. The company's 2022 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the first quarter of 2022, as both cannot be reliably forecasted.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and gastroenterology, in addition to products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.

Conference Call
 
AbbVie will host an investor conference call today at 8:00 a.m. Central time to discuss our first-quarter performance. The call will be webcast through AbbVie’s Investor Relations website at investors.abbvie.com. An archived edition of the call will be available after 11:00 a.m. Central time.

Non-GAAP Financial Results
 
Financial results for 2022 and 2021 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with GAAP and include all revenue and expenses recognized during the period. Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release. Beginning in the first quarter of 2022, the company includes the impact of upfront and milestone payments related to collaborations, licensing agreements, and other asset acquisitions in its reported non-GAAP financial measures. Prior periods have been revised to conform to the current period presentation. AbbVie’s management believes non-GAAP financial measures provide useful information to investors regarding AbbVie’s results of operations and assist management, analysts, and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP.



6


Forward-Looking Statements
 
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the failure to realize the expected benefits of AbbVie’s acquisition of Allergan or to promptly and effectively integrate Allergan’s business, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2021 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
 
Media:Investors:
Frank BenenatiLiz Shea
(224) 688-4169(847) 935-2211
  
 Todd Bosse
 (847) 936-1182
  
 Jeffrey Byrne
 (847) 938-2923


7


AbbVie Inc.
Key Product Revenues
Quarter Ended March 31, 2022
(Unaudited)
    % Change vs. 1Q21
 Net Revenues (in millions)Reported
Operationala
U.S.Int’l.TotalU.S.Int’l.TotalInt’l.Total
NET REVENUES$10,348$3,190$13,5386.1%(2.1)%4.1%3.2%5.4%
Immunology5,0851,0566,1419.7(4.9)6.91.18.1
Humira3,9937434,7362.2(22.6)(2.7)(17.9)(1.8)
Skyrizi78115994062.371.263.782.965.6
Rinvoq31115446526.8>100.053.6>100.057.3
Hematologic Oncology1,1025441,646(9.8)20.9(1.6)24.7(0.6)
Imbruvicab
8742991,173(12.4)11.0(7.4)11.0(7.4)
Venclexta2282454731.735.816.945.221.1
Aesthetics8465281,37416.327.920.533.522.5
Botox Cosmetic41322864135.532.534.438.636.6
Juvederm Collection14826241020.132.227.537.730.9
Other Aesthetics28538323(4.9)(9.9)(5.5)(6.2)(5.0)
Neuroscience1,2732151,48822.72.019.28.820.4
Botox Therapeutic50011461416.510.715.417.116.6
Vraylar42742723.4n/a23.4n/a23.4
Duodopa2497121(5.6)(6.9)(6.7)0.5(0.8)
Ubrelvy13813870.0n/a70.0n/a70.0
Qulipta1111n/mn/an/mn/an/m
Other Neuroscience173417711.011.411.012.211.0
Eye Care496275771(6.3)(4.2)(5.6)3.7(2.8)
Lumigan/Ganfort67731401.5(5.7)(2.4)0.71.0
Alphagan/Combigan7037107(11.5)(3.9)(9.0)5.5(6.0)
Restasis23511246(11.9)(18.1)(12.2)1.9(11.3)
Other Eye Care1241542785.5(2.4)0.94.85.1
Other Key Products6892189074.3(13.4)(0.6)(6.7)1.2
Mavyret169211380(1.0)(13.9)(8.6)(7.2)(4.6)
Creon2872874.7n/a4.7n/a4.7
Linzess/Constella23372407.96.07.810.27.9
a "Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.
b Reflects profit sharing for Imbruvica international revenues.
n/a = not applicable
n/m = not meaningful

8


AbbVie Inc.
Consolidated Statements of Earnings
Quarter Ended March 31, 2022 and 2021
(Unaudited) (In millions, except per share data)
 
 First Quarter
Ended March 31
20222021
Net revenues$13,538 $13,010 
Cost of products sold4,052 4,213 
Selling, general and administrative3,127 2,842 
Research and developmenta
1,497 1,667 
Acquired IPR&D and milestonesa
145 185 
Total operating costs and expenses8,821 8,907 
Operating earnings4,717 4,103 
Interest expense, net539 622 
Net foreign exchange loss25 
Other income, net(776)(395)
Earnings before income tax expense4,929 3,867 
Income tax expense436 312 
Net earnings4,493 3,555 
Net earnings attributable to noncontrolling interest
Net earnings attributable to AbbVie Inc.$4,490 $3,553 
Diluted earnings per share attributable to AbbVie Inc.$2.51 $1.99 
Adjusted diluted earnings per shareb
$3.16 $2.89 
Weighted-average diluted shares outstanding1,778 1,775 

a    During the three months ended March 31, 2022, AbbVie changed its classification of development milestone expense associated with licensing and collaboration arrangements in the consolidated statement of earnings. Milestone payments incurred prior to regulatory approval, which were previously included in research and development expense, are now presented as acquired IPR&D and milestones expense. The reclassification decreased research and development expense and increased acquired IPR&D and milestones expense by $115 million for the three months ended March 31, 2021. The company believes this presentation assists users of the financial statements to better understand the total upfront and subsequent development milestone payments incurred to acquire in-process research and development projects. Prior periods have been revised to conform to the current period presentation. The reclassification had no impact on total operating costs and expenses, operating earnings, net earnings, net earnings attributable to AbbVie, Inc., earnings per share, or total equity.

b    Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details.




9


AbbVie Inc.
Reconciliation of GAAP Reported to Non-GAAP Adjusted Information
Quarter Ended March 31, 2022
(Unaudited) (In millions, except per share data)
1. Specified items impacted results as follows:
 1Q22
 EarningsDiluted
 Pre-tax
After-taxa
EPS
As reported (GAAP)$4,929 $4,490 $2.51 
Adjusted for specified items:   
Intangible asset amortization1,855 1,565 0.88 
Acquisition and integration costs138 121 0.07 
Change in fair value of contingent consideration (748)(746)(0.42)
Litigation matters184 148 0.08 
Other64 63 0.04 
As adjusted (non-GAAP)$6,422 $5,641 $3.16 
a     Represents net earnings attributable to AbbVie Inc.
Acquisition and integration costs reflect integration costs related to the Allergan acquisition. Other primarily includes restructuring charges associated with streamlining global operations.
Beginning in the first quarter of 2022, the company includes the impact of upfront and milestone payments related to collaborations, licensing agreements, and other asset acquisitions in its reported non-GAAP financial measures. Reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2022 included acquired IPR&D and milestones expense of $145 million on a pre-tax and after-tax basis, representing an unfavorable impact of $0.08 to both diluted EPS and adjusted diluted EPS.
2. The impact of the specified items by line item was as follows: 
 1Q22
 Cost of products soldSG&AR&DOther income, net
As reported (GAAP)$4,052 $3,127 $1,497 $(776)
Adjusted for specified items:
Intangible asset amortization(1,855)— — — 
Acquisition and integration costs(34)(93)(11)— 
Change in fair value of contingent consideration — — — 748 
Litigation matters— (184)— — 
Other(60)(6)— 
As adjusted (non-GAAP)
$2,103 $2,852 $1,480 $(28)
3. The adjusted tax rate for the first quarter of 2022 was 12.1 percent, as detailed below:
 1Q22
Pre-tax earningsIncome taxesTax rate
As reported (GAAP)$4,929 $436 8.8 %
Specified items1,493 342 22.9 %
As adjusted (non-GAAP)
$6,422 $778 12.1 %

10


AbbVie Inc.
Reconciliation of GAAP Reported to Non-GAAP Adjusted Information
Quarter Ended March 31, 2021
(Unaudited) (In millions, except per share data)
 
1. Specified items impacted results as follows:
 1Q21
 EarningsDiluted
 Pre-tax
After-taxa
EPS
As reported (GAAP)$3,867 $3,553 $1.99 
Adjusted for specified items:   
Intangible asset amortization2,009 1,682 0.94 
Acquisition and integration costs224 155 0.09 
Change in fair value of contingent consideration (343)(343)(0.19)
Other141 112 0.06 
As adjusted (non-GAAP)$5,898 $5,159 $2.89 
a     Represents net earnings attributable to AbbVie Inc.
Acquisition and integration costs reflect integration costs as well as amortization of the acquisition date fair value step-up for inventory related to the Allergan acquisition. Other primarily includes the purchase of an FDA priority review voucher from a third party, restructuring charges associated with streamlining global operations and COVID-19 related expenses.
Beginning in the first quarter of 2022, the company includes upfront and milestone payments related to collaborations, licensing agreements, and other asset acquisitions in its reported non-GAAP financial measures. Reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2021 included acquired IPR&D and milestones expense of $185 million on a pre-tax and $168 million on an after-tax basis, representing an unfavorable impact of $0.09 to both diluted EPS and adjusted diluted EPS.
2. The impact of the specified items by line item was as follows: 
 1Q21
 Cost of products soldSG&AR&DOther income, net
As reported (GAAP)$4,213 $2,842 $1,667 $(395)
Adjusted for specified items:
Intangible asset amortization(2,009)— — — 
Acquisition and integration costs(99)(76)(49)— 
Change in fair value of contingent consideration— — — 343 
Other(20)(23)(113)15 
As adjusted (non-GAAP)
$2,085 $2,743 $1,505 $(37)
3. The adjusted tax rate for the first quarter of 2021 was 12.5 percent, as detailed below:
 1Q21
Pre-tax earningsIncome taxesTax rate
As reported (GAAP)$3,867 $312 8.1 %
Specified items2,031 425 20.9 %
As adjusted (non-GAAP)
$5,898 $737 12.5 %

11
EX-101.SCH 3 abbv-20220429.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 abbv-20220429_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 abbv-20220429_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Sec 2.125 Senior Notes Due 2029 Sec 2.125 Senior Notes Due 2029 [Member] Sec 2.125 Senior Notes Due 2029 CHICAGO STOCK EXCHANGE, INC CHICAGO STOCK EXCHANGE, INC [Member] Entity Address, State or Province Entity Address, State or Province Sec 1.375 Senior Notes Due 2024 Sec 1.375 Senior Notes Due 2024 [Member] Sec 1.375 Senior Notes Due 2024 [Member] Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Entity Emerging Growth Company Entity Emerging Growth Company Soliciting Material Soliciting Material City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Listings, Exchange [Axis] Entity Listings, Exchange [Axis] Entity Address, Address Line One Entity Address, Address Line One Entity Information [Line Items] Entity Information [Line Items] Sec 1.500 Senior Notes Due 2023 Sec 1.500 Senior Notes Due 2023 [Member] Sec 1.500 Senior Notes Due 2023 Local Phone Number Local Phone Number Cover [Abstract] Cover [Abstract] Sec 1.250 Senior Notes Due 2024 Sec 1.250 Senior Notes Due 2024 [Member] Sec 1.250 Senior Notes Due 2024 Sec 0.750 Senior Notes Due 2027 Sec 0.750 Senior Notes Due 2027 [Member] Sec 0.750 Senior Notes Due 2027 [Member] Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Common Stock Common Stock [Member] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Exchange [Domain] Exchange [Domain] Sec 1.250 Senior Notes due 2031 Sec 1.250 Senior Notes due 2031 [Member] Sec 1.250 Senior Notes due 2031 [Member] Trading Symbol Trading Symbol Sec 2.125 Senior Notes due 2028 Sec 2.125 Senior Notes due 2028 [Member] Sec 2.125 Senior Notes due 2028 [Member] Document Period End Date Document Period End Date NEW YORK STOCK EXCHANGE, INC. NEW YORK STOCK EXCHANGE, INC. [Member] Class of Stock [Domain] Class of Stock [Domain] Document Type Document Type Class of Stock [Axis] Class of Stock [Axis] Entity Registrant Name Entity Registrant Name Sec 2.625 Senior Notes Due 2028 Sec 2.625 Senior Notes Due 2028 [Member] Sec 2.625 Senior Notes Due 2028 Entity Address, City or Town Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entities [Table] Entities [Table] Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 6 abbv-20220429_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 abbvieimage1a53.jpg begin 644 abbvieimage1a53.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information Document
Apr. 29, 2022
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date Apr. 29, 2022
Entity Registrant Name ABBVIE INC.
Entity Central Index Key 0001551152
Amendment Flag false
Entity Incorporation, State or Country Code DE
Entity File Number 001-35565
Entity Tax Identification Number 32-0375147
Entity Address, Address Line One 1 North Waukegan Road
Entity Address, City or Town North Chicago
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60064-6400
City Area Code 847
Local Phone Number 932-7900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security Common Stock, $0.01 Par Value
Trading Symbol ABBV
Security Exchange Name NYSE
Common Stock | CHICAGO STOCK EXCHANGE, INC  
Entity Information [Line Items]  
Title of 12(b) Security Common Stock, $0.01 Par Value
Trading Symbol ABBV
Security Exchange Name CHX
Sec 1.500 Senior Notes Due 2023 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 1.500% Senior Notes due 2023
Trading Symbol ABBV23B
Security Exchange Name NYSE
Sec 1.375 Senior Notes Due 2024 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 1.375% Senior Notes due 2024
Trading Symbol ABBV24
Security Exchange Name NYSE
Sec 1.250 Senior Notes Due 2024 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 1.250% Senior Notes due 2024
Trading Symbol ABBV24B
Security Exchange Name NYSE
Sec 0.750 Senior Notes Due 2027 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 0.750% Senior Notes due 2027
Trading Symbol ABBV27
Security Exchange Name NYSE
Sec 2.125 Senior Notes due 2028 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 2.125% Senior Notes due 2028
Trading Symbol ABBV28
Security Exchange Name NYSE
Sec 2.625 Senior Notes Due 2028 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 2.625% Senior Notes due 2028
Trading Symbol ABBV28B
Security Exchange Name NYSE
Sec 2.125 Senior Notes Due 2029 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 2.125% Senior Notes due 2029
Trading Symbol ABBV29
Security Exchange Name NYSE
Sec 1.250 Senior Notes due 2031 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 1.250% Senior Notes due 2031
Trading Symbol ABBV31
Security Exchange Name NYSE
XML 9 abbv-20220429_htm.xml IDEA: XBRL DOCUMENT 0001551152 2022-04-29 2022-04-29 0001551152 us-gaap:CommonStockMember exch:XNYS 2022-04-29 2022-04-29 0001551152 us-gaap:CommonStockMember exch:XCHI 2022-04-29 2022-04-29 0001551152 abbv:Sec1500SeniorNotesDue2023Member exch:XNYS 2022-04-29 2022-04-29 0001551152 abbv:Sec1.375SeniorNotesDue2024Member exch:XNYS 2022-04-29 2022-04-29 0001551152 abbv:Sec1250SeniorNotesDue2024Member exch:XNYS 2022-04-29 2022-04-29 0001551152 abbv:Sec0.750SeniorNotesDue2027Member exch:XNYS 2022-04-29 2022-04-29 0001551152 abbv:Sec2.125SeniorNotesdue2028Member exch:XNYS 2022-04-29 2022-04-29 0001551152 abbv:Sec2625SeniorNotesDue2028Member exch:XNYS 2022-04-29 2022-04-29 0001551152 abbv:Sec2125SeniorNotesDue2029Member exch:XNYS 2022-04-29 2022-04-29 0001551152 abbv:Sec1.250SeniorNotesdue2031Member exch:XNYS 2022-04-29 2022-04-29 0001551152 false 8-K 2022-04-29 ABBVIE INC. DE 001-35565 32-0375147 1 North Waukegan Road North Chicago IL 60064-6400 847 932-7900 false false false false Common Stock, $0.01 Par Value Common Stock, $0.01 Par Value ABBV ABBV NYSE CHX 1.500% Senior Notes due 2023 ABBV23B NYSE 1.375% Senior Notes due 2024 ABBV24 NYSE 1.250% Senior Notes due 2024 ABBV24B NYSE 0.750% Senior Notes due 2027 ABBV27 NYSE 2.125% Senior Notes due 2028 ABBV28 NYSE 2.625% Senior Notes due 2028 ABBV28B NYSE 2.125% Senior Notes due 2029 ABBV29 NYSE 1.250% Senior Notes due 2031 ABBV31 NYSE false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 11 22 1 false 11 0 false 0 false false R1.htm 0001001 - Document - Document and Entity Information Document Sheet http://www.abbvie.com/role/DocumentandEntityInformationDocument Document and Entity Information Document Cover 1 false false All Reports Book All Reports abbv-20220429.htm abbv-20220331xexhibit991.htm abbv-20220429.xsd abbv-20220429_def.xml abbv-20220429_lab.xml abbv-20220429_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "abbv-20220429.htm": { "axisCustom": 0, "axisStandard": 2, "contextCount": 11, "dts": { "definitionLink": { "local": [ "abbv-20220429_def.xml" ] }, "inline": { "local": [ "abbv-20220429.htm" ] }, "labelLink": { "local": [ "abbv-20220429_lab.xml" ] }, "presentationLink": { "local": [ "abbv-20220429_pre.xml" ] }, "schema": { "local": [ "abbv-20220429.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd" ] } }, "elementCount": 40, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 8, "memberStandard": 3, "nsprefix": "abbv", "nsuri": "http://www.abbvie.com/20220429", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abbv-20220429.htm", "contextRef": "i390d04c256c347f6b6f64c60f0020e1f_D20220429-20220429", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document and Entity Information Document", "role": "http://www.abbvie.com/role/DocumentandEntityInformationDocument", "shortName": "Document and Entity Information Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abbv-20220429.htm", "contextRef": "i390d04c256c347f6b6f64c60f0020e1f_D20220429-20220429", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 11, "tag": { "abbv_Sec0.750SeniorNotesDue2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sec 0.750 Senior Notes Due 2027 [Member]", "label": "Sec 0.750 Senior Notes Due 2027 [Member]", "terseLabel": "Sec 0.750 Senior Notes Due 2027" } } }, "localname": "Sec0.750SeniorNotesDue2027Member", "nsuri": "http://www.abbvie.com/20220429", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "domainItemType" }, "abbv_Sec1.250SeniorNotesdue2031Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sec 1.250 Senior Notes due 2031 [Member]", "label": "Sec 1.250 Senior Notes due 2031 [Member]", "terseLabel": "Sec 1.250 Senior Notes due 2031" } } }, "localname": "Sec1.250SeniorNotesdue2031Member", "nsuri": "http://www.abbvie.com/20220429", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "domainItemType" }, "abbv_Sec1.375SeniorNotesDue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sec 1.375 Senior Notes Due 2024 [Member]", "label": "Sec 1.375 Senior Notes Due 2024 [Member]", "terseLabel": "Sec 1.375 Senior Notes Due 2024" } } }, "localname": "Sec1.375SeniorNotesDue2024Member", "nsuri": "http://www.abbvie.com/20220429", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "domainItemType" }, "abbv_Sec1250SeniorNotesDue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sec 1.250 Senior Notes Due 2024", "label": "Sec 1.250 Senior Notes Due 2024 [Member]", "terseLabel": "Sec 1.250 Senior Notes Due 2024" } } }, "localname": "Sec1250SeniorNotesDue2024Member", "nsuri": "http://www.abbvie.com/20220429", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "domainItemType" }, "abbv_Sec1500SeniorNotesDue2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sec 1.500 Senior Notes Due 2023", "label": "Sec 1.500 Senior Notes Due 2023 [Member]", "terseLabel": "Sec 1.500 Senior Notes Due 2023" } } }, "localname": "Sec1500SeniorNotesDue2023Member", "nsuri": "http://www.abbvie.com/20220429", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "domainItemType" }, "abbv_Sec2.125SeniorNotesdue2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sec 2.125 Senior Notes due 2028 [Member]", "label": "Sec 2.125 Senior Notes due 2028 [Member]", "terseLabel": "Sec 2.125 Senior Notes due 2028" } } }, "localname": "Sec2.125SeniorNotesdue2028Member", "nsuri": "http://www.abbvie.com/20220429", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "domainItemType" }, "abbv_Sec2125SeniorNotesDue2029Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sec 2.125 Senior Notes Due 2029", "label": "Sec 2.125 Senior Notes Due 2029 [Member]", "terseLabel": "Sec 2.125 Senior Notes Due 2029" } } }, "localname": "Sec2125SeniorNotesDue2029Member", "nsuri": "http://www.abbvie.com/20220429", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "domainItemType" }, "abbv_Sec2625SeniorNotesDue2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sec 2.625 Senior Notes Due 2028", "label": "Sec 2.625 Senior Notes Due 2028 [Member]", "terseLabel": "Sec 2.625 Senior Notes Due 2028" } } }, "localname": "Sec2625SeniorNotesDue2028Member", "nsuri": "http://www.abbvie.com/20220429", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_EntityListingsExchangeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Listings, Exchange [Axis]", "terseLabel": "Entity Listings, Exchange [Axis]" } } }, "localname": "EntityListingsExchangeAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "employerIdItemType" }, "dei_ExchangeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.", "label": "Exchange [Domain]", "terseLabel": "Exchange [Domain]" } } }, "localname": "ExchangeDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "exch_XCHI": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHICAGO STOCK EXCHANGE, INC [Member]", "terseLabel": "CHICAGO STOCK EXCHANGE, INC" } } }, "localname": "XCHI", "nsuri": "http://xbrl.sec.gov/exch/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "domainItemType" }, "exch_XNYS": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW YORK STOCK EXCHANGE, INC. [Member]", "terseLabel": "NEW YORK STOCK EXCHANGE, INC." } } }, "localname": "XNYS", "nsuri": "http://xbrl.sec.gov/exch/2021", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001551152-22-000012-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001551152-22-000012-xbrl.zip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end